Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0745411 (irregular bleeding)
 386 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Contraceptive implants containing progestin have been marketed in Finland since 1984. The method utilizes 6 silicon capsules of 36 mg levonorgestrel that are implanted inside the upper arm under local anesthesia. Each capsule is 34 mm long and 2.5 mm wide. The capsules release 100 mcg levonorgestrel a day during the 1st 3 months, after which dosage decreases to a level of 30-35 mcg a day within 15 months. The rate of release remains the same for a period of up to 6.5 years. Some users experience no ovulation or an incomplete luteal phase. The level of estradiol varies, although FSH, LH and androgen levels do no essentially change. Cholesterol ratios remain unchanged, but the levels decrease somewhat. Blood coagulation problems due to menstrual problems, primarily frequent, irregular bleeding and spotting. Side effects such as headaches, weight gain, mood changes can be caused by the capsule, as well as the contraceptive pill. During implantation and removal there is a small (0.3) risk of infection. Teratogenic and mutagenic effects are unlikely. Studies have shown no pregnancies occurring in the 1st 2 years of use. The 3rd year, the cumulative rate has been shown to be 0.3, and for the 4th year 0.7. To a great extent, contraceptive implants are utilized by women who have had bad experiences with other methods, and who already have the desired number of children. This method offers much promise to those women in developing countries, and has been proven to be well tolerated there.
 ...
PMID:[Subcutaneous hormone capsules]. 333 Nov 42